MX2010003445A - Derivados de nicotinamida, su preparacion y su uso terapeutico. - Google Patents

Derivados de nicotinamida, su preparacion y su uso terapeutico.

Info

Publication number
MX2010003445A
MX2010003445A MX2010003445A MX2010003445A MX2010003445A MX 2010003445 A MX2010003445 A MX 2010003445A MX 2010003445 A MX2010003445 A MX 2010003445A MX 2010003445 A MX2010003445 A MX 2010003445A MX 2010003445 A MX2010003445 A MX 2010003445A
Authority
MX
Mexico
Prior art keywords
group
preparation
hydrogen atom
therapeutic use
nicotinamide derivatives
Prior art date
Application number
MX2010003445A
Other languages
English (en)
Inventor
Pierre Casellas
Samir Jegham
Pierre Fraisse
Monsif Bouaboula
Jerome Arigon
Claude Bernhart
Romain Combet
Sandrine Hilairet
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MX2010003445A publication Critical patent/MX2010003445A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invenci?n se refiere a un compuesto de f?rmula (I) en la que: A es un grupo NR1R'1 o alcoxi de 1 a 6 ?tomos de carbono; en donde Z y Z' son N y CH; N y CF; N y N; CH y CH; CH y N respectivamente; L es un grupo -CH=CH- ? -CH2CH2- o -(CH2)n-Y-; R1 y R'1 son tal como: (i) R1 representa: un ?tomo de hidr?geno, un grupo arilo opcionalmente sustituido por uno o m?s ?tomos de hal?geno, un grupo heteroarilo, un grupo cicloalquilo de 3 a 6 ?tomos de carbono, un grupo alquilo de 1 a 6 ?tomos de carbono y R'1 es un ?tomo de hidr?geno o un grupo alquilo de 1 a 6 ?tomos de carbono, o (ii) R1 y R'1 forman junto con el ?tomo de nitr?geno al cual est?n unidos un grupo heterocicloalquilo; R2 representa un grupo de Q-R4 Q es un ?tomo de ox?geno o el grupo -NH-; R4 es: un ?tomo de hidr?geno, un grupo heteroarilo, un grupo cicloalquilo de 3 a 6 ?tomos de carbono, un grupo alquilo de 1 a 6 ?tomos de carbono, opcionalmente sustituido, R3 representa al menos un sustituyente del n?cleo piridina.
MX2010003445A 2007-09-28 2008-09-26 Derivados de nicotinamida, su preparacion y su uso terapeutico. MX2010003445A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0706799A FR2921657A1 (fr) 2007-09-28 2007-09-28 Derives de nicotinamide, leur preparation et leur application en therapeutique
PCT/FR2008/001338 WO2009074749A2 (fr) 2007-09-28 2008-09-26 Dérives de nicotinamide. leur préparation et leur application en thérapeutique

Publications (1)

Publication Number Publication Date
MX2010003445A true MX2010003445A (es) 2010-04-27

Family

ID=39356668

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010003445A MX2010003445A (es) 2007-09-28 2008-09-26 Derivados de nicotinamida, su preparacion y su uso terapeutico.

Country Status (19)

Country Link
US (1) US20100222319A1 (es)
EP (1) EP2205566A2 (es)
JP (1) JP2010540504A (es)
KR (1) KR20100065165A (es)
CN (1) CN101808996A (es)
AR (1) AR066171A1 (es)
AU (1) AU2008334457A1 (es)
BR (1) BRPI0817973A2 (es)
CA (1) CA2700559A1 (es)
CL (1) CL2008002893A1 (es)
FR (1) FR2921657A1 (es)
IL (1) IL204663A0 (es)
MX (1) MX2010003445A (es)
PA (1) PA8797301A1 (es)
PE (1) PE20091033A1 (es)
RU (1) RU2010116765A (es)
TW (1) TW200918056A (es)
UY (1) UY31367A1 (es)
WO (1) WO2009074749A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006311650B2 (en) 2005-11-08 2012-02-23 Vertex Pharmaceuticals Incorporated Heterocyclic modulators of ATP-binding cassette transporters
EP2789606B1 (en) 2007-05-09 2017-11-15 Vertex Pharmaceuticals Incorporated Modulators of CFTR
SI2639222T1 (sl) 2007-12-07 2016-12-30 Vertex Pharmaceuticals Incorporated Proces za izdelavo cikloalkilkarboksiamido-piridin benzojskih kislin
RS55559B1 (sr) 2007-12-07 2017-05-31 Vertex Pharma Čvrste forme 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il) benzoeve kiseline
CN106432213A (zh) 2008-02-28 2017-02-22 沃泰克斯药物股份有限公司 作为cftr调节剂的杂芳基衍生物
FR2943675A1 (fr) * 2009-03-24 2010-10-01 Sanofi Aventis Composes anticancereux, leur preparation et leur application en therapeutique
FR2943670B1 (fr) * 2009-03-24 2011-05-06 Sanofi Aventis Derives anticancereux,leur preparation et leur application en therapeutique
FR2943669B1 (fr) * 2009-03-24 2011-05-06 Sanofi Aventis Derives de nicotinamide,leur preparation et leur application en therapeutique
WO2010144647A1 (en) * 2009-06-12 2010-12-16 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
US8912184B1 (en) 2010-03-01 2014-12-16 Alzheimer's Institute Of America, Inc. Therapeutic and diagnostic methods
EP2542086A4 (en) * 2010-03-01 2013-09-04 Myrexis Inc COMPOUNDS AND ITS THERAPEUTIC USE
SI3150198T1 (sl) 2010-04-07 2021-11-30 Vertex Pharmaceuticals Incorporated Farmacevtski sestavki 3-(6-(1-(2,2-difluorobenzo(D)(1,3)dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzojske kisline in dajanje le-teh
US8827372B2 (en) 2010-07-07 2014-09-09 Frontis Corp. Blowing system
FR2965263A1 (fr) * 2010-09-24 2012-03-30 Sanofi Aventis Derives de thienopyridine nicotinamide, leur preparation et leur application en therapeutique
US9169246B2 (en) 2011-09-26 2015-10-27 Sanofi Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof
EP2573073B1 (en) * 2011-09-26 2014-10-22 Sanofi Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof
CN103012397B (zh) * 2011-09-26 2017-03-01 赛诺菲 吡唑并喹啉酮衍生物、其制备方法及其治疗用途
DK3068392T5 (da) 2013-11-12 2021-09-20 Vertex Pharma Fremgangsmåde til fremstilling af farmaceutiske sammensætninger til behandlingen af cftr-medierede sygdomme
CN103804270B (zh) * 2014-01-23 2016-06-22 中国药科大学 5-(4-甲脒基苄氧基)色氨酸衍生物、其制法及应用
BR112017010406B1 (pt) 2014-11-18 2021-03-09 Vertex Pharmaceuticals Incorporated processo de realização de teste de alta produtividade de cromatografia líquida de alta eficiência
CN107522641B (zh) * 2016-06-22 2020-05-05 复旦大学 联芳基脲类衍生物或其盐及其制备方法和用途
JP7092356B2 (ja) 2016-06-22 2022-06-28 フーダン ユニヴァーシティ ビアリール尿素誘導体またはそれらの塩、およびそれらの調製方法および使用
US20220324842A1 (en) * 2018-05-04 2022-10-13 Remedy Plan, Inc. Cancer treatments targeting cancer stem cells
CN110396065A (zh) * 2019-06-25 2019-11-01 南京普锐达医药科技有限公司 一种2,4-二氯-5-嘧啶甲酰氯的合成方法
MX2022005445A (es) * 2019-11-06 2022-08-10 Remedy Plan Inc Tratamientos contra el cáncer dirigidos a las células madre cancerosas.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4301110A1 (de) * 1993-01-18 1994-07-21 Bayer Ag Verfahren zur Herstellung von 2-Amino-5-aminomethyl-pyridin
KR20010086112A (ko) * 1998-12-16 2001-09-07 빌프리더 하이더 인테그린 길항제로서의 신규한 비페닐 및 비페닐 유사화합물
DE10063008A1 (de) * 2000-12-16 2002-06-20 Merck Patent Gmbh Carbonsäureamidderivate
US20040067985A1 (en) * 2002-10-04 2004-04-08 Fortuna Haviv Method of inhibiting angiogenesis
JP2007515400A (ja) * 2003-11-28 2007-06-14 ノバルティス アクチエンゲゼルシャフト タンパク質キナーゼ依存性疾患の処置におけるジアリール尿素誘導体
US20060216288A1 (en) * 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer

Also Published As

Publication number Publication date
RU2010116765A (ru) 2011-11-27
BRPI0817973A2 (pt) 2019-04-09
PA8797301A1 (es) 2009-05-15
CL2008002893A1 (es) 2009-10-16
JP2010540504A (ja) 2010-12-24
AU2008334457A1 (en) 2009-06-18
FR2921657A1 (fr) 2009-04-03
CA2700559A1 (fr) 2009-06-18
UY31367A1 (es) 2009-04-30
IL204663A0 (en) 2010-11-30
WO2009074749A2 (fr) 2009-06-18
PE20091033A1 (es) 2009-08-17
EP2205566A2 (fr) 2010-07-14
AR066171A1 (es) 2009-07-29
KR20100065165A (ko) 2010-06-15
CN101808996A (zh) 2010-08-18
WO2009074749A3 (fr) 2009-08-20
TW200918056A (en) 2009-05-01
US20100222319A1 (en) 2010-09-02

Similar Documents

Publication Publication Date Title
MX2010003445A (es) Derivados de nicotinamida, su preparacion y su uso terapeutico.
NO20092770L (no) Nye aminopyrimidinderivater som PLK1-inhibitorer
MX2010008361A (es) Derivados de arilamida oxazepinopirimidona sustituidos.
RS54708B1 (en) ARYLETINYL DERIVATIVES
EP1953154A4 (en) CINNAMIDE COMPOUNDS OF MORPHOLINE TYPE
MX2009002802A (es) Derivados de 2-aril-6-fenil-imidazo[1,2-a]piridinas, su preparacion y su aplicacion en terapeutica.
MX2009012380A (es) Compuestos de heteroarilamida pirimidona.
ME01029B (me) VIŠESUPTITUISANI DERIVATI 2-ARIL-6-FENIL-IMIDAZO [1, 2α] PIRIDINI, NJIHOVO DOBIJANJE I NJIHOVA UPOTREBA U TERAPIJI
AR087328A1 (es) Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak
NO20066015L (no) Fuserte heterosykliske forbindelser
EA201170099A1 (ru) Замещенные пиримидин-4-оновые производные
WO2010089510A3 (fr) Dérivés d'azaspiranyl-alkylcarbamates d'hétérocycles à 5 chaînons, leur préparation et leur application en thérapeutique
MX2010008362A (es) Derivados de heteroarilamida diazepinopirimidona sustituidos.
NO20082976L (no) Svovelholdige cykliske ureaderivater, fremstilling derav og farmasoytisk anvendelse derav som kinaseinhibitorer
MX2010008360A (es) Derivados de oxazepinopirimidona heteroarilamida sustituidos.
MX2009011212A (es) Derivados de triazolopiridina carboxamida y triazolopirimidina carboxamida, su preparacion y su aplicacion terapeutica.
MX2010008637A (es) Derivado de fenilpirrol novedoso.
NO20080738L (no) Fremgangsmater for neurobeskyttelse
WO2008136444A1 (ja) 縮合複素環誘導体
EA201170098A1 (ru) Замещенные производные алкилпиримидин-4-она
CO6321168A2 (es) Nuevos derivados de 2-amidotiadiazol
EA201071012A1 (ru) Производные азетидинов, способ их получения и применение их в терапии
EA200971063A1 (ru) Ариламидпиримидоновые соединения
MX2009012383A (es) Derivados de arilamida pirimidona para el tratamiento de enfermedades neurodegenerativas.
NO20085308L (no) Dualmolekyler inneholdende et peroksidderivat, deres syntese og deres terapautiske anvendelser

Legal Events

Date Code Title Description
FA Abandonment or withdrawal